{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:12:21Z","timestamp":1770693141079,"version":"3.49.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In the phase 3 ECHELON-2 trial, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) significantly improved progression-free survival (PFS) and overall survival (OS) compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30+ peripheral T-cell lymphoma, benefits that were maintained at 5 years. Interim positron emission tomography (PET) scan can be used to assess prognosis and risk-stratify patients. The prognostic value of interim PET was assessed in this post hoc exploratory analysis from ECHELON-2, evaluating interim 18F-fluorodeoxyglucose PET scans after cycle 4 (PET4) and end-of-treatment\u2013based response, and correlated with PFS per investigator and OS. PET4 response was determined by Deauville score (scores of 1-3 were considered negative [PET4-negative] and 4-5 positive [PET4-positive]) by independent review. Overall, 452 patients were randomized 1:1 to the BV-CHP (n = 226) and CHOP (n = 226) arms. Of these, 32 in the BV-CHP arm and 41 in the CHOP arm were not evaluable for PET4. In both arms, PET4-negative status was associated with improved PFS (BV-CHP: HR, 0.36; 95% CI, 0.19-0.66; CHOP: HR, 0.26; 95% CI, 0.17-0.41) and OS (BV-CHP: HR, 0.38; 95% CI, 0.18-0.78; CHOP: HR, 0.24; 95% CI, 0.14-0.41) compared with PET4-positive status. Among patients with systemic anaplastic large cell lymphoma, PET4-negative patients had improved PFS (BV-CHP: HR, 0.28; 95% CI, 0.14-0.60; CHOP: HR, 0.31; 95% CI, 0.17-0.56) and OS (BV-CHP: HR, 0.38; 95% CI, 0.16-0.94; CHOP: HR, 0.25; 95% CI, 0.12-0.55) compared with PET4-positive patients. In this exploratory analysis, PET4-negative status by Deauville score was associated with improved long-term PFS and OS in both the BV-CHP and CHOP arms. This trial was registered at www.ClinicalTrials.gov as #NCT01777152.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015282","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T20:05:51Z","timestamp":1755633951000},"page":"5976-5987","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1646-813X","authenticated-orcid":false,"given":"Swaminathan","family":"Iyer","sequence":"first","affiliation":[{"name":"1Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"3Department of Medicine\/Oncology, Stanford Cancer Institute, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob H.","family":"Christensen","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Odense University Hospital, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital Center University de Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-090X","authenticated-orcid":false,"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[{"name":"6Hematology Department, Institut Catal\u00e0 d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-5344","authenticated-orcid":false,"given":"Onder","family":"Alpdogan","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"10Lymphoma Division, Hackensack University Medical Center, Hackensack, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-007X","authenticated-orcid":false,"given":"Vincent","family":"Camus","sequence":"additional","affiliation":[{"name":"11Department of Hematology and INSERM U1245, Centre Henri Becquerel, University of Rouen, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Gritti","sequence":"additional","affiliation":[{"name":"12Hematology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"13Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine\u2013Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Mayer","sequence":"additional","affiliation":[{"name":"15Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"16Department of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-0921","authenticated-orcid":false,"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Rustia","sequence":"additional","affiliation":[{"name":"18Pfizer Inc, Bothell, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keenan","family":"Fenton","sequence":"additional","affiliation":[{"name":"18Pfizer Inc, Bothell, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"18Pfizer Inc, Bothell, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"19Division of Medical Oncology, The University of British Columbia, Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"20Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"25","key":"2025120910162335500_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025120910162335500_bib2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025120910162335500_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"17","key":"2025120910162335500_bib4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","article-title":"How I treat the peripheral T-cell lymphomas","volume":"123","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2025120910162335500_bib5","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"2025120910162335500_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"10168","key":"2025120910162335500_bib7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2025120910162335500_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025120910162335500_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2967\/jnumed.117.193946","article-title":"Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients","volume":"59","author":"Cottereau","year":"2018","journal-title":"J Nucl Med"},{"issue":"suppl 5","key":"2025120910162335500_bib10","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","article-title":"Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"d'Amore","year":"2015","journal-title":"Ann Oncol"},{"key":"2025120910162335500_bib11","volume-title":"Adcetris. US prescribing information","year":"2023"},{"issue":"4","key":"2025120910162335500_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2025120910162335500_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"2025120910162335500_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/bloodadvances.2018024075","article-title":"Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma","volume":"3","author":"Mehta-Shah","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2025120910162335500_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12880-021-00674-5","article-title":"The role of pre-treatment and mid-treatment 18F-FDG PET\/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Med Imaging"},{"key":"2025120910162335500_bib16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/01.HS9.0000847612.86972.11","article-title":"End of treatment 18F FDG-PET\/CT response is prognostic for overall and progression-free survival in peripheral T-cell lymphoma: results of the UK NCRI phase 2 randomised CHEMO-T trial PET\/CT substudy","volume":"6","author":"Gleeson","year":"2022","journal-title":"Hemasphere"},{"issue":"5","key":"2025120910162335500_bib17","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","article-title":"CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial","volume":"5","author":"Gleeson","year":"2018","journal-title":"Lancet Haematol"},{"key":"2025120910162335500_bib18","author":"Swerdlow","year":"2008","edition":"4th ed"},{"issue":"5","key":"2025120910162335500_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025120910162335500_bib20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/asheducation.V2012.1.397.3798512","article-title":"Interim PET-CT in the management of diffuse large B-cell lymphoma","volume":"2012","author":"Moskowitz","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"27","key":"2025120910162335500_bib21","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025120910162335500_bib22","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1038\/bcj.2016.2","article-title":"The prognostic value of interim and end-of-treatment PET\/CT in patients with newly diagnosed peripheral T-cell lymphoma","volume":"6","author":"Ham","year":"2016","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2025120910162335500_bib23","article-title":"Impact of front-line treatment interim PET\/CT in peripheral T-cell lymphoma patients\u2019 survival: experience of a single center","volume":"142","author":"Rampi","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025120910162335500_bib24","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025120910162335500_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-cell lymphomas, version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025120910162335500_bib26","doi-asserted-by":"crossref","first-page":"S413","DOI":"10.1016\/S2152-2650(23)01279-X","article-title":"Does interim PET assessment after two cycles of treatment with brentuximab vedotin still have a predictive value in Hodgkin lymphoma? Clin","volume":"23","author":"Samaeekia","year":"2023","journal-title":"Lymphoma Myeloma Leuk"},{"issue":"suppl 15","key":"2025120910162335500_bib27","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): impact of cycle 2 PET result on modified progression-free survival (mPFS)","volume":"36","author":"Chen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10450","key":"2025120910162335500_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"2025120910162335500_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1186\/s12885-016-2886-9","article-title":"Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer","volume":"16","author":"Amin","year":"2016","journal-title":"BMC Cancer"},{"issue":"1127","key":"2025120910162335500_bib30","doi-asserted-by":"crossref","first-page":"20210448","DOI":"10.1259\/bjr.20210448","article-title":"Total tumor burden in lymphoma - an evolving strong prognostic parameter","volume":"94","author":"Meignan","year":"2021","journal-title":"Br J Radiol"},{"issue":"1","key":"2025120910162335500_bib31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12916-022-02562-3","article-title":"Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"2025120910162335500_bib32","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4143\/crt.2022.017","article-title":"Circulating tumor DNA-based genotyping and monitoring for predicting disease relapses of patients with peripheral T-cell lymphomas","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"issue":"4","key":"2025120910162335500_bib33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdw011","article-title":"Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET\/CT in patients with peripheral T-cell lymphoma (PTCL)","volume":"27","author":"Cottereau","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"2025120910162335500_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13550-020-00698-y","article-title":"Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)","volume":"10","author":"Jiang","year":"2020","journal-title":"EJNMMI Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/5976\/2423311\/blooda_adv-2024-015282-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/23\/5976\/2423311\/blooda_adv-2024-015282-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:19:13Z","timestamp":1765293553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/23\/5976\/546755\/Association-of-PET4-response-with-outcomes-of-BV"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015282","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,9]]},"published":{"date-parts":[[2025,11,26]]}}}